Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M350Revenue (TTM) $M6.3Net Margin (%)400Altman Z-Score5.7
Enterprise Value $M338EPS (TTM) $0.2Operating Margin %-1,102.0Piotroski F-Score4
P/E(ttm)15.0Beneish M-Score-2.9Pre-tax Margin (%)136Higher ROA y-yY
Price/Book2.710-y EBITDA Growth Rate %32.4Quick Ratio4.2Cash flow > EarningsN
Price/Sales46.35-y EBITDA Growth Rate %28.0Current Ratio4.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)25.0Higher Current Ratio y-yY
Dividend Yield %--PEG0.5ROE % (ttm)49.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M111ROIC % (ttm)-124.9Gross Margin Increase y-yY

Gurus Latest Trades with BTX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

BTX is held by these investors:



BTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BROADWOOD PARTNERS, L.P.Director, 10% Owner 2017-02-15Buy2,222,222$2.716.67view
BROADWOOD PARTNERS LPDirector, 10% Owner 2016-06-21Buy2,732,636$2.3931.8view
BROADWOOD PARTNERS LPDirector, 10% Owner 2016-01-20Buy300,000$2.3534.04view
KINGSLEY ALFRED DSee Remarks, 10% Owner 2016-01-20Sell300,000$2.3534.04view
FARRELL STEPHEN CDirector 2015-11-06Buy50,000$3.83-17.75view
Russell Angus C.Director 2015-11-06Buy50,000$3.83-17.75view
KINGSLEY ALFRED DSee Remarks, 10% Owner 2015-11-06Sell100,000$3.83-17.75view
ANDREWS DEBORAH JDirector 2015-08-26Buy2,000$2.8211.7view
Cartt Stephen LaHueDirector 2015-08-18Buy75,000$2.812.5view
Russell Angus C.Director 2014-12-12Sell0$012.5view

Quarterly/Annual Reports about BTX:

News about BTX:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
6:46 am BioTime announced the deconsolidation of OncoCyte Inc.'s financial statements from its... Feb 21 2017
BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary Feb 21 2017
BIOTIME INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... Feb 21 2017
BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 15 2017
BioTime, Inc. Announces Closing of Public Offering of Common Stock Feb 15 2017
CORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement... Feb 15 2017
BioTime to Present at Two Upcoming Investor Conferences Feb 13 2017
BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Feb 13 2017
BioTime Declares $17.5M Public Stock Offering Feb 10 2017
BioTime, Inc. Announces Pricing of Public Offering of Common Stock Feb 10 2017
BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 09 2017
BioTime, Inc. Announces Proposed Public Offering of Common Stock Feb 09 2017
Acorda, Amgen and Regeneron Lead Premarket Biotech Movers Feb 09 2017
BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel Feb 07 2017
BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation... Feb 06 2017
LifeSci Capital Initiates Coverage of BioTime, Inc. Jan 30 2017
BioTime to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference Jan 26 2017
Additional Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to be Presented at ARVO 2017 Jan 19 2017
BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : January 12, 2017 Jan 12 2017
BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing... Jan 03 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)